Comparative Pharmacology
Head-to-head clinical analysis: BRIMONIDINE TARTRATE TIMOLOL MALEATE versus CORGARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIMONIDINE TARTRATE TIMOLOL MALEATE versus CORGARD.
BRIMONIDINE TARTRATE; TIMOLOL MALEATE vs CORGARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brimonidine is a selective alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow. Timolol is a non-selective beta-adrenergic receptor blocker that decreases aqueous humor production by inhibiting beta-2 receptors in the ciliary epithelium.
Nonselective beta-adrenergic receptor antagonist; competitively blocks beta1- and beta2-adrenergic receptors, leading to decreased heart rate, myocardial contractility, and blood pressure. Also prolongs sinoatrial node refractory period and inhibits renin release.
One drop of the fixed combination (0.2% brimonidine/0.5% timolol) in the affected eye(s) twice daily, approximately 12 hours apart.
40 mg orally once daily for hypertension; initial dose 40 mg once daily for angina, titrate up to 80-240 mg once daily. Maximum dose 320 mg/day.
None Documented
None Documented
Brimonidine: ~3 hours (terminal); timolol: ~4–6 hours (terminal). Clinical context: allows twice-daily dosing for brimonidine/timolol combination.
Terminal elimination half-life: 20-24 hours (may extend to 40 hours in renal impairment). Clinical context: Allows once-daily dosing; steady-state achieved in 5-7 days.
Brimonidine: primarily renal (74% as unchanged drug); timolol: renal (20% unchanged, remainder as metabolites) and fecal (small amount).
Renal (unchanged, ~85-90%); fecal (<5%); biliary (<2%).
Category A/B
Category C
Beta-Blocker
Beta-Blocker